NICOLE GOITIA: Open Payments
NPI 1578124947 · ENGLEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,109 in 136 payments from 23 companies in 2025. Trend: 2023 $2,275 · 2024 $2,474 · 2025 $3,109
Food & beverage: $3,109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $874 |
| Gilead Sciences, Inc. | 15 | $289 |
| Janssen Biotech, Inc. | 9 | $282 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $224 |
| Lilly USA, LLC | 5 | $207 |
| GENZYME CORPORATION | 6 | $149 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $143 |
| Phathom Pharmaceuticals, Inc. | 7 | $126 |
| PFIZER INC. | 7 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
Products named: TREMFYA, RINVOQ, SKYRIZI, OMVOH, DUPIXENT, ENTYVIO, XIFAXAN, LINZESS.
Industry payments across CO — which companies pay providers there.
